Všeobecná fakultní nemocnice v Praze

The Všeobecná fakultní nemocnice v Praze (VFN) is a leading and the largest research healthcare institution in the Czech Republic with a rich tradition of academic medicine dating back to its founding in 1790. It serves as the main teaching base for the 1st Faculty of Medicine at Charles University, offering a wide range of basic, specialized, and highly specialized medical, nursing, outpatient, and diagnostic care for both children and adults across all fundamental medical disciplines. With around 5,700 employees and nearly 2,000 beds, VFN annually treats 45,000 inpatients and over 1.5 million outpatients. VFN's core programs encompass intensive medicine, cardiology, oncology, maternal and child care, psychiatry and addiction, as well as hereditary metabolic disorders and other rare diseases. Notably, the institution pioneers cutting-edge medical practices, including the use of extracorporeal membrane oxygenation (ECMO) to temporarily substitute heart and lung function, the implementation of subcutaneous sensors for monitoring glycemia in diabetes patients, and the utilization of artificial intelligence and machine learning in ophthalmology, nuclear medicine, and radiation oncology. Furthermore, VFN has been at the forefront in applying the drug remdesivir in the treatment of COVID-19 patients, performing cardiothoracic surgeries for primary pulmonary hypertension, and managing hereditary metabolic disorders. As a state-funded organization under the direct auspices of the Czech Republic's Ministry of Health, VFN embodies a commitment to providing top-notch, high-tech medical care at a global standard. With its groundbreaking medical interventions and extensive research, VFN stands poised to attract strategic investments and partnerships from local and international venture capital firms looking to support and advance the forefront of healthcare innovation.